Cancer
Immunotherapy Conference Agenda
|
Day 1 |
|
|
7:30 |
Registration |
|
8:00 |
Opening
Remarks |
|
8:15 |
Keynote Address:
Immunotherapy: Making the Immune System Great Again |
|
James Gulley, M.D., Ph.D. |
|
|
Session I |
Therapeutic
Vaccines |
|
9:00 |
The Evolving Role of
Cancer Vaccines |
|
Col. (ret.) George E.
Peoples, M.D., FACS, MC, USA |
|
|
9:20 |
In Situ Vaccination to Potential Checkpoint Blockade: Optimizing
Cross-Presentation in Mouse and Man. And Woman |
|
Joshua Brody, M.D. |
|
|
9:40 |
AutoSynVax Overview |
|
Robert Stein, M.D.,
Ph.D. |
|
|
9:50 |
pLADD Overview |
|
Thomas W. Dubensky,
Jr., Ph.D. Chief Scientific
Officer |
|
|
10:00 |
Therapeutic Vaccine Panel Discussion |
|
10:45 |
Break |
|
Session II |
Immunomodulators |
|
11:00 |
Immunotherapy: What’s Genes Got to Do With It? |
|
Timothy Chan M.D., Ph.D. Vice Chair, Department of Radiation
Oncology; Director–Translational Oncology Division; Member–Human Oncology & Pathogenesis
Program; Director–Immunogenomics and Precision
Oncology Platform; Paine Webber Chair in Cancer Genetics Memorial Sloan Kettering Cancer Center |
|
|
11:15 |
Direct Activation of
STING for Cancer Immunotherapy |
|
Thomas W. Dubensky,
Jr., Ph.D. Chief Scientific
Officer |
|
|
11:30 |
NKTR-214, a T-cell
Growth Engine for Immuno-Oncology |
|
Deborah Charych, Ph.D. Executive Director–Research and Development Nektar Therapeutics |
|
|
11:45 |
Systematic Targeting of
Immune Cells to Treat Cancer |
|
Robert Sikorski, M.D.,
Ph.D. |
|
|
12:00 |
TLR9 Agonists in Cancer
Immunotherapy |
|
Robert Coffman, Ph.D. |
|
|
12:15 |
Lunch |
|
1:00 |
Immunomodulator Panel
Discussion |
|
Session III |
Adoptive
Cell Therapies |
|
1:55 |
CD19-Targeted Car-T Cells: Past, Present, & Future |
|
Marco Davila, M.D., Ph.D. Associate Member, Department of Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and Research Institute |
|
|
2:10 |
TCRs for Solid Tumors |
|
Helen Tayton-Martin,
Ph.D. Chief Operating Officer Adaptimmune |
|
|
2:25 |
Synthetic Regulation of
T Cells |
|
David Spencer, Ph.D. Chief Scientific
Officer Bellicum Pharmaceuticals |
|
|
2:40 |
HPV Targeted T-Cells
for HPV Associated Cancers |
|
Christian Hinrichs M.D. Investigator, Experimental Transplantation and Immunology Branch,
Lasker Clinical Research Scholar, Center for Cancer Research National Cancer Institute |
|
|
2:55 |
Break |
|
3:15 |
Allogeneic CAR-T
Therapy |
|
André Choulika, Ph.D. Chief Executive Officer Cellectis |
|
|
3:30 |
Title to be Determined |
|
|
Christian Itin, Ph.D. Chief Executive Officer Autolus |
|
3:45 |
Adoptive Cell Therapy
Panel Discussion |
|
5:00 |
Reception |
|
Day 2 |
|
|
7:30 |
Registration |
|
8:15 |
Keynote Address:
Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms |
|
Jedd Wolchok, M.D., Ph.D. Lloyd J. Old/Virginia and Daniel K.
Ludwig Chair in Clinical Investigation; Chief, Melanoma &
Immunotherapeutics Service; Director–Parker Institute for Cancer
Immunotherapy at Memorial Sloan Kettering Cancer Center; Associate Director–Ludwig
Center for Cancer Immunotherapy; Member–Ludwig Cancer Research; Professor of
Medicine, Weill Medical College of Cornell University |
|
|
Session IV |
Immunotherapy
Combination Approaches |
|
9:00 |
Title to Be Determined |
|
Bristol-Myers Squibb |
|
|
9:20 |
Targeting the Tumor
Microenvironment in Combination with Checkpoint Inhibitors |
|
Miriam Merad, M.D., Ph.D. Professor of Medicine, Hematology,
and Medical Oncology Mount Sinai |
|
|
9:40 |
Immunotherapy
Combinations: Science Informing Clinical Studies |
|
|
Christoffer Boshoff, M.D., Ph.D. Senior Vice President,
Immuno-Oncology, Early Development and Translational Oncology Pfizer Inc. |
|
10:00 |
Break |
|
10:20 |
Title to Be Determined |
|
Jeffery Kutok, M.D., Ph.D. Chief Scientific Officer Infinity Pharmaceuticals |
|
|
10:40 |
Title to Be Determined |
|
Eric
Hedrick, M.D. Clinical
Advisor BeiGene |
|
|
11:00 |
Emerging Next
Generation Checkpoint Modulators |
|
Robert Stein, M.D., Ph.D. |
|
|
11:20 |
Development of Rational
Combinations in Immuno-oncology |
|
Michael Kalos, Ph.D. |
|
|
11:40 |
Lunch Presentation and Panel Discussions by INC Research |
|
|
Laura Vidal, M.D. Senior Medical Director-Global
Oncology & Hematology INC Research |
|
1:00 |
Ideas Put Into Practice
– Combination Therapies in Lung Cancer |
|
Speaker to Be Determined |
|
|
2:00 |
Borrowing from the
Military Strategy in Immunotherapy War |
|
James Gulley, M.D., Ph.D. |
|
|
2:20 |
Immunosequencing in the
Service of Immuno-oncology |
|
|
Ilan "Lanny" Kirsch, M.D. |
|
2:40 |
Break |
|
2:55 |
Title to Be Determined |
|
John Lin, M.D., Ph.D. Vice President, Immune Oncology & Head, Regeneron Bispecific
R&D Regeneron |
|
|
3:15 |
Immunotherapy
Combinations Panel Discussion |
|
4:15 |
Reception |
|
Speakers |
|
|
|
Christoffel
Boshoff, MD, Ph.D. Senior Vice President, Immuno-Oncology, Early Development and
Translational Oncology Pfizer Inc. |
|
|
Joshua
Brody, M.D. Director–Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine |
|
|
Timothy Chan M.D., Ph.D. Vice
Chair, Department of Radiation Oncology; Director–Translational
Oncology Division; Member–Human
Oncology & Pathogenesis Program; Director–Immunogenomics
and Precision Oncology Platform; Paine
Webber Chair in Cancer Genetics Memorial
Sloan Kettering Cancer Center |
|
|
Deborah Charych, Ph.D. Executive Director–Research and
Development Nektar Therapeutics |
|
|
André Choulika, Ph.D. Chief Executive Officer Cellectis |
|
|
Robert
Coffman, Ph.D. Senior Vice President and Chief Scientific Officer Dynavax |
|
|
Marco Davila, M.D.,
Ph.D. Associate Member, Department of
Blood and Marrow Transplantation H. Lee Moffitt Cancer Center and
Research Institute |
|
|
Thomas W.
Dubensky, Jr., Ph.D. Chief Scientific Officer Aduro Biotech |
|
|
James Gulley, M.D., Ph.D. Chief–Genitourinary Malignancies
Branch; Director–Medical Oncology Service Center for Cancer Research, NIH |
|
|
Eric Hedrick, M.D. Clinical
Advisor BeiGene |
|
|
Christian Hinrichs M.D. Investigator, Experimental
Transplantation and Immunology Branch, Lasker Clinical Research Scholar,
Center for Cancer Research National Cancer Institute |
|
|
Christian Itin, Ph.D. Chief Executive Officer Autolus |
|
Speakers |
|
|
|
Michael
Kalos, Ph.D. Chief Scientific Officer, Cancer Immunobiology Lilly Research Laboratories, Eli Lilly & Company |
|
|
Ilan
"Lanny" Kirsch, M.D. Senior Vice President–Translational Medicine Adaptive Biotechnologies |
|
|
Jeffery
Kutok, M.D., Ph.D. Chief Scientific Officer Infinity Pharmaceuticals |
|
|
Helen
Tayton-Martin, Ph.D. Chief Operating Officer Adaptimmune |
|
|
John Lin,
M.D., Ph.D. Vice President, Immune Oncology & Head, Regeneron Bispecific
R&D Regeneron |
|
|
Miriam Merad, M.D.,
Ph.D. Professor of Medicine, Hematology,
and Medical Oncology Mount Sinai |
|
|
Col. (ret.)
George E. Peoples, M.D., FACS, MC, USA Founder and CEO, Cancer Insight, LLC; Director–Cancer Vaccine Development Program; Professor of Surgery, Uniformed Services University; Professor (adjunct) of Surgical Oncology, MD Anderson Cancer
Center |
|
|
Robert
Sikorski, M.D., Ph.D. Senior Vice President and Chief Medical Officer Five Prime Therapeutics |
|
|
David Spencer, Ph.D. Chief Scientific Officer Bellicum Pharmaceuticals |
|
|
Robert Stein,
M.D., Ph.D. President–Research
and Development and CSO Agenus |
|
|
Laura Vidal, M.D. Senior Medical Director-Global
Oncology & Hematology INC Research |
|
|
Jedd Wolchok, M.D.,
Ph.D. Lloyd J. Old/Virginia and Daniel K.
Ludwig Chair in Clinical Investigation; Chief, Melanoma &
Immunotherapeutics Service; Director–Parker Institute for Cancer
Immunotherapy at Memorial Sloan Kettering Cancer Center; Associate
Director–Ludwig Center for Cancer Immunotherapy; Member–Ludwig Cancer
Research; Professor of Medicine, Weill Medical College of Cornell University |